In the search for novel signaling pathways involved in MECP2-related syndromes and potential quantitative biomarkers, we selected an exploratory cohort of 20 RTT females with a known mutation in MECP2, 2 males with MDS and 28 healthy controls. This evidence concerns the gene MECP2 and myelodysplastic syndrome.